Schedule of Related Party Transactions |
The following table summarizes the Company’s related party transactions (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | Related Party and Nature of Transaction | Caption in Balance Sheet and Statement of Operations | | 2024 | | 2023 | | 2024 | | 2023 | Kashiv Biosciences LLC | | | | | | | | | | Sale of subsidiary - gain on sale | Other income, net | | $ | — | | | $ | — | | | $ | (3,760) | | | $ | — | | Sale of subsidiary - interest income on loan receivable | Interest expense, net | | $ | (198) | | | $ | — | | | $ | (330) | | | $ | — | | Parking space lease | Research and development | | $ | 25 | | | $ | 25 | | | $ | 75 | | | $ | 75 | | Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate | Research and development | | $ | — | | | $ | (75) | | | $ | — | | | $ | (25) | | Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra) | Cost of goods sold | | $ | 3,021 | | | $ | 844 | | | $ | 11,741 | | | $ | 988 | | Storage agreement | Research and development | | $ | (63) | | | $ | (18) | | | $ | (189) | | | $ | (100) | | Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra) | Inventory and cost of goods sold | | $ | 2,783 | | | $ | 90 | | | $ | 6,425 | | | $ | 590 | | Generic development supply agreement - research and development material | Research and development | | $ | (633) | | | $ | (2,209) | | | $ | (681) | | | $ | (2,209) | | Generic development supply agreement - development activity deferred income | Accounts payable and accrued expenses and net revenue | | $ | — | | | $ | (246) | | | $ | (422) | | | $ | (246) | | Development and commercialization agreement - Long-acting injectable | Research and development | | $ | — | | | $ | — | | | $ | 500 | | | $ | — | | Development and commercialization agreement - Omaluzimab | Research and development | | $ | 20,000 | | | $ | — | | | $ | 20,000 | | | $ | — | | | | | | | | | | | | Other Related Parties | | | | | | | | | | Sellers Notes - interest expense | Interest expense, net | | $ | 266 | | | $ | — | | | $ | 9,986 | | | $ | — | | Kanan, LLC - operating lease | Inventory and cost of goods sold | | $ | 592 | | | $ | 592 | | | $ | 1,776 | | | $ | 1,750 | | Sutaria Family Realty, LLC - operating lease | Inventory and cost of goods sold | | $ | 324 | | | $ | 314 | | | $ | 962 | | | $ | 933 | | Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement | Inventory and cost of goods sold | | $ | 4,689 | | | $ | 5,528 | | | $ | 14,910 | | | $ | 11,095 | | Tracy Properties LLC - operating lease | Selling, general and administrative | | $ | 98 | | | $ | 258 | | | $ | 462 | | | $ | 521 | | AzaTech Pharma LLC - supply agreement | Inventory and cost of goods sold | | $ | 3,771 | | | $ | 2,588 | | | $ | 9,016 | | | $ | 5,132 | | AvPROP, LLC - operating lease | Selling, general and administrative | | $ | 45 | | | $ | 44 | | | $ | 139 | | | $ | 134 | | Avtar Investments, LLC - consulting services | Research and development | | $ | 66 | | | $ | 70 | | | $ | 195 | | | $ | 267 | | Alkermes | Inventory and cost of goods sold | | $ | 83 | | | $ | 232 | | | $ | 189 | | | $ | 322 | | R&S Solutions - logistics services | Selling, general and administrative | | $ | — | | | $ | 46 | | | $ | — | | | $ | 86 | | Members - tax receivable agreement (TRA liability) | Increase in tax receivable agreement liability | | $ | 11,327 | | | $ | 677 | | | $ | 26,719 | | | $ | 1,908 | |
The following table summarizes the amounts due to or from the Company for related party transactions (in thousands): | | | | | | | | | | | | | September 30, 2024 | | December 31, 2023 | Kashiv - sale of subsidiary, including interest | $ | 7,474 | | | $ | — | | Kashiv - various agreements | 1,096 | | | 954 | | Alkermes | 7 | | | 1 | | AzaTech Pharma LLC - supply agreement | 2 | | | — | | Related party receivables - short term | $ | 8,579 | | | $ | 955 | | | | | | Kashiv - various agreements | $ | 5,309 | | | $ | 3,179 | | Apace Packaging, LLC - packaging agreement | 1,335 | | | 1,091 | | AzaTech Pharma LLC - supply agreement | 1,923 | | | 1,958 | | Avtar Investments LLC - consulting services | 64 | | | 100 | | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes | — | | | 442 | | Members - tax receivable agreement | 4,289 | | | 549 | | Alkermes Plc | 2 | | | 2 | | Related party payables - short term | $ | 12,922 | | | $ | 7,321 | | | | | | Kashiv - contingent consideration | $ | — | | | $ | 430 | | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes | — | | | 8,139 | | Members - tax receivable agreement | 26,186 | | | 3,207 | | Related party payables - long term | $ | 26,186 | | | $ | 11,776 | |
|